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AbstrAct
Esophageal adenocarcinomas (EAC) are aggressive tumors with considerable 
rates of chemoresistance. Autophagy is a lysosome-dependent degradation process, 
characterized by the formation of vesicles called autophagosomes, and has been 
implicated in cancer. Protein light chain 3 B (LC3B) and p62 are associated with 
autophagosomal membranes and degraded. We aimed to assess the impact of basal 
autophagy on EAC. In EAC cell lines, an increase in LC3B and p62 was observed with 
increasing concentrations of the autophagy inhibitor chloroquine, which indicates 
functional basal autophagy. LC3B and p62 immunohistochemistry was performed 
on primary resected EAC. High LC3B and p62 expression was associated with earlier 
tumor stages (p < 0.05). High nuclear and cytoplasmic p62 staining were associated 
with a better prognosis (p = 0.006; p = 0.028). Various combinations of p62 expression 
with or without LC3B expression identified different prognostic groups. Tumors with 
low total p62 (p = 0.007) or low LC3B/low p62 expression had the worst outcome 
(p = 0.007; p = 0.005). A combination score of dot-like/cytoplasmic p62 and nuclear 
p62 staining was an independent prognostic parameter (p = 0.033; HR = 0.6). This 
study highlights the potential significance of basal autophagy in EAC biology. Tumors 
with low LC3B and p62 expression show the most aggressive behavior and may be 
candidates for autophagy regulating therapeutics.
IntroductIon
Esophageal Adenocarcinomas (EAC), usually 
arising from metaplastic Barrett’s esophagus (BE), 
are highly aggressive tumors and often locally and 
systemically advanced upon diagnosis. Furthermore, 
the incidence is increasing in developed countries [1]. 
Treatment for locally advanced disease has improved with 
refined surgical techniques and the advent of neoadjuvant 
chemotherapy. However, the therapeutic options for 
recurrent and metastatic disease are mainly limited to 
(radio)chemotherapy leading to an overall poor prognosis 
for EAC [2]. Alternative therapeutic strategies, which also 
may encompass targeting molecular events/regulation, 
would therefore be highly desirable. 
Macroautophagy (hereafter referred to as autophagy) 
is a cellular catabolic process for the degradation and 
recycling of cellular components such as proteins and 
organelles. The process is tightly regulated and highly 
conserved. Under basal conditions autophagy maintains 
homeostasis. Autophagy is a pro-survival mechanism 
under cellular stresses, such as nutrient deprivation, as it 
frees up building blocks and energy for essential processes 
[3]. The dysregulation of autophagy has been implicated 
in many diseases including neurodegenerative diseases. In 
cancer autophagy has demonstrated diverging roles, being 
described as both pro- and anti-oncogenic. It is theorized 
that autophagy can have a tumor suppressor function 
in early stages as it degrades deleterious proteins and 
maintains genomic stability. However, later on autophagy 
can be exploited by neoplastic cells as a survival 
mechanism enabling progression, invasion, metastasis and 
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evading cell death upon treatment [4]. Autophagy also has 
diverging roles with respect to tumor immune surveillance 
given its effect on the tumor microenvironment and 
function in antigen presentation [5, 6]. Therefore the 
first aim of this study was to confirm functional basal 
autophagy in EAC cell lines. Functional basal autophagy 
can be defined as the continual autophagic flux under 
steady state culture conditions in the absence of chemo-, 
radio or targeted therapy. This is of relevance given the 
recent characterization of cancer cell lines lacking core 
autophagy machinery components and consequently 
proving unable to undergo functional basal autophagic 
flux [7, 8]. While cancer cell lines lacking functional 
basal autophagy are rare, in light of recent discoveries, this 
proof of principle experiment was of import. Functional 
basal autophagy can be assessed via the markers LC3B 
and p62 in the absence and presence of pharmacological 
autophagy inhibition. Cytosolic LC3B-I is lipidated and 
incorporated into the autophagosomal membrane, forming 
the LC3B-II isoform. LC3B-II is subsequently degraded 
during autophagic flux [9]. As LC3B-II is membrane-
bound and subsequently degraded, the accumulation of 
this isoform upon pharmacological autophagy inhibition is 
indicative of intact basal autophagy. LC3B-II can also be 
visualized via immunofluorescence as punctae. Similarly, 
the accumulation of p62, which is also associated with the 
autophagosomal membrane and subject to degradation, 
upon pharmacological autophagy inhibition is also an 
indicator of functional basal autophagy [9]. The second 
aim was to assess basal autophagy in EAC ex vivo. 
Immunohistochemical LC3B and p62 dot-like staining is 
considered to be indicative of autophagosomes and may 
therefore be used as markers in patient tissue. Using a 
previously established staining and scoring protocol [10] 
LC3B and p62 immunohistochemistry was performed 
on next generation tissue microarrays (ngTMAs) of 
formalin fixed paraffin embedded (FFPE) samples of 
primary resected EAC, Barrett’s mucosa, adjacent non-
neoplastic esophageal mucosa, adjacent non-neoplastic 
gastric mucosa, EAC lymph node metastasis and EAC 
distant metastasis and the results were then correlated with 
clinicopathological parameters. 
results
eAc exhibits intact basal autophagy in vitro
To access functional basal autophagy in EAC 
in vitro the autophagy markers LC3B and p62 were 
assessed via immunoblotting and immunofluorescence 
upon pharmacological autophagy inhibition with 
chloroquine. EAC cell lines OE19 and OE33 were 
treated with chloroquine (CQ) for 48 hours followed by 
immunoblotting for LC3B and p62, with total protein 
was visualized as loading control. A dose-dependent 
increase of both proteins was observed with increasing 
concentrations of CQ, which is indicative of functional 
basal autophagy (Figure 1). This result was verified by 
immunofluorescence staining in both cell lines as a dose-
dependent increase in LC3B-II punctae with increasing 
concentrations of CQ was observed, confirming functional 
basal autophagy (Figure 2). 
clinicopathological and prognostic implications of 
autophagy markers in eAc tissue
Median age of the patient cohort was 69 years 
(ranging from 32 to 89 years). Male/female ratio was 
100/16. The pT category (according to UICC 2009 
[11]) was as follows: pT1 - 35 cases (30.2%), pT2 - 11 
cases (9.5%), pT3 - 67 cases (57.8%) and pT4 3 cases 
(2.6%). Lymph node metastases were absent in 56 
cases (48.3%) and present in 60 cases (51.7%). Distant 
metastases at the time of surgery were present in 5 
cases (4.3%). Lymphatic invasion was present in 78 
cases (67.2%), venous invasion in 29 cases (25%) and 
perineural invasion present in 45 cases (38.8%). Tumor 
grading was classified as G1 (well differentiated) in 18 
cases (15.4%), G2 (moderately differentiated) in 50 
cases (43.1%) and G3 (poorly differentiated) in 48 cases 
(41.4%). Intratumoral inflammation was low in 55 cases 
(47.4%) and high in 61 cases (52.6%). Complete tumor 
resection (R0) was achieved in 109 cases (93.9%). The 
median overall survival, which was calculated from the 
day of surgical resection until last contact or death, was 
28 months (ranging from 0 to 208 months). Patient data is 
summarized in Table 1. 
In primary resected EAC and primary resected non-
dysplastic and dysplastic Barrett’s mucosa we observed 
LC3B (Figure 3) and p62 dot-like staining patterns ranging 
from absent (score 0) to strong (score 3) with detection of 
abundant immunoreactive dots. Similarly a range of p62 
cytoplasmic staining was observed and both negative and 
positive p62 nuclear staining was reported (Figure 4). 
LC3B and p62 dot-like immunostaining showed a positive 
association (p = 0.020) in primary resected EAC tumors. 
A positive association between individual p62 dot-like and 
p62 cytoplasmic staining scores was observed (p = 0.005). 
See Supplemental material for all correlations between 
individual staining scores (Supplementary Table 1.1 to 
Supplementary Table 2.3).
Staining patterns were homogenous for LC3B 
and all scoring categories of p62 across the tumors. 
Intratumoral heterogeneity, defined as more than one of 
the six tumor punches (three taken from tumor center and 
three taken from tumor periphery) showing discrepancies 
greater than 1 scoring point, was in the explicit minority. 
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The tumors showed higher amounts of LC3B dots, as 
well as p62 dot-like, cytoplasmic and nuclear staining, 
when compared to normal gastric and esophageal mucosa 
(ranging from p < 0.001 to p < 0.02). For LC3B there 
was no significant difference between primary tumor and 
metastases (p = 0.301 for lymph node and p = 0.083 for 
distant metastases). For p62, higher p62 dot-like staining 
was observed in distant metastases compared to primary 
tumors (p = 0.022) and higher nuclear staining was 
observed in lymph node metastases compared to primary 
tumors (p = 0.021), whereas no difference was seen 
between the primary tumors and lymph node and distant 
metastases for cytoplasmic p62 staining (p = 0.835 and p 
= 0.480), neither for p62 dot-like staining regarding lymph 
node metastases (p = 0.777) and for p62 nuclear staining 
regarding distant metastases (p = 0.132).
For the purpose of further analysis IHC scores were 
categorized as either “low” or “high” based on prognostic 
table 1: summary of patient data
Parameter category total Percentage (%)
Median age - 69 years -
Sex Male Female
100
16
86.2
13.8
pT category (T) pT1
pT2
pT3
pT4
35
11
67
3
30.2
9.5
57.8
2.6
Lymph Node Metastasis (N)
pN0
pN1
pN2
pN3
56
19
22
19
48.3
16.4
19.0
16.4
Distant Metastasis (M) absent
present
111
5
95.7
4.3
UICC Stage
IA
IB
IIA
IIB
IIIA
IIIB
IIIC
IV
32
3
18
7
16
17
18
5
27.4
2.6
15.4
6.0
13.8
14.7
15.5
4.3
Lymphatic Invasion (L) absentpresent
38
78
32.8
67.2
Venous Invasion (V) absentpresent
87
29
75.0
25.0
Perineural Invasion (Pn) absentpresent
71
45
61.2
38.8
Grading (G)
G1
G2
G3
18
50
48
15.5
43.1
41.4
Inflammation lowhigh
55
61
47.4
52.6
Resection Status (R) R0R1
109
7
94.0
6.0
table 2: summary of staining patterns
staining Pattern low High
LC3B dots 97 (83.6%)
19 
(16.4%)
p62 dots 48(41.4%)
68
(58.6%)
p62 cytoplasm 12(10.3%)
104
(89.7%)
p62 nuclear 58(50.0%)
58
(50.0%)
p62 sum 22(19.0%)
94
(81.0%)
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impact as outlined in the Materials and Methods 
section. Categories for low and high for each staining is 
summarized in Table 2. Low/high groupings of p62 dots 
and cytoplasmic staining showed a statistically significant 
correlation (p = 0.026). For correlations of all low/high 
p62 groups please see Supplementary Table 3.1 to 3.3. The 
association of low and high groups of LC3B dot-like, p62 
dot-like, p62 cytoplasmic, p62 nuclear and p62 sum scores 
with clinicopathological features pT category, presence of 
lymph node or distant metastases, clinical stage, lymphatic 
invasion, venous invasion, perineural invasaion, grading, 
inflammation and resection status was assessed. LC3B 
dot-like staining did not significantly correlate with any of 
those clinicopathological features (Table 3). In contrast, 
low p62 nuclear staining correlated with lymph node 
metastases (p = 0.015), as well as with higher grade (p = 
0.042; Table 4). Strikingly, no stage I tumors with low p62 
cytoplasmic expression were observed (p = 0.021; Table 
4). In line with this finding, fewer stage I tumors had low 
p62 nuclear expression (p = 0.042; Table 4). Similarly only 
two stage I tumors had a low p62 sum score (p = 0.017; 
Table 5). Taken together these results indicated that low 
levels of p62 correlate with a more aggressive phenotype 
(Table 4; Table 5). 
Low/high groupings of staining patterns versus 
overall survival were investigated using univariate 
analysis. Low p62 cytoplasmic staining, p62 nuclear 
staining and p62 sum score all significantly correlated with 
a worse overall survival with p-values equaling 0.028, 
0.006 and 0.007 respectively (and in trend p62 dot-like 
staining p = 0.078; Figure 5). Low LC3B was associated 
with worse outcome as well, but this was not statistically 
significant (p = 0.335; see Supplementary Figure 1 for 
LC3B survival curve). 
According to work published by Iwade et al. and 
Liu et al. we subclassified our cohort based on p62 and 
LC3B expression and subcellular localization of p62 as 
described in the Materials and Methods section [12, 13]. 
The p62 cytoplasmic/p62 nuclear LL category correlated 
with the worst overall survival, the p62 cytoplasmic/p62 
nuclear HH category with the best overall survival, while 
both the HL and LH categories showed intermediate 
survival rates (p = 0.003, data not shown), which justified 
a combination of these groups into a “mixed” group 
(Figure 6A). Similarly, the LC3B/p62 LL group faired the 
worse when compared to HH and mixed subtypes (p = 
0.013, Figure 6B). When comparing the LL group with 
the remainder of all other cases grouped together it also 
showed the worse overall survival (p = 0.005, data not 
shown). 
Other prognostic relevant parameters were pT 
category (p = 0.001), pN category (p = 0.002), presence 
of distant metastases (p = 0.045), lymphatic vessel 
invasion (p = 0.034), and UICC staging (p = 0.001), and 
in trend the presence of perineural invasion (p = 0.058), 
but not resection status, venous invasion and intratumoral 
inflammation (p = 0.485, p = 0.434 and p = 0.406 
respectively).
table 3: lc3b dot-like staining and clinicopathological features
Parameter category total lc3b low lc3b High p -value
pT category pT1
pT2
pT3
pT4
35
11
67
3
26
9
59
3
9
2
8
0
0.283
Lymph Node 
Metastasis
absent
present
56
60
47
50
9
10 1.000
Distant Metastasis absentpresent
111
5
93
4
18
1 1.000
UICC Stage
I
II
III
IV
35
25
51
5
26
24
43
4
9
1
8
1
0.165
Lymphatic 
Invasion
absent 
present
38
78
31
66
7
12 0.790
Venous Invasion absentpresent
87
29
73
24
14
5 1.000
Perineural Invasion absentpresent
71
45
57
40
14
5 0.305
Grading
G1
G2
G3
18
50
48
12
42
43
6
8
5
0.158
Inflammation lowhigh
55
61
47
50
8
11 0.802
Resection Status R0R1
109
7
90
7
19
0 0.597
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In a multivariate analysis encompassing the relevant 
prognostic factors pT category, lymph node and distant 
metastases, grading, lymphatic and perineural invasion, 
the classification strategy of p62 cytoplasmic/p62 nuclear 
(where cytoplasmic also includes dot-like staining) showed 
the highest significance level for prognostic discrimination 
and was an independent prognostic parameter (p = 0.033, 
HR = 0.561; Table 6). p62 cytoplasmic/p62 nuclear 
staining was also independent prognostic factor in a model 
encompassing tumor grading and UICC stage (p = 0.021; 
Table 7).
dIscussIon
In the present study we aimed to assess the role 
of basal autophagy in EAC. We observed intact basal 
autophagy in EAC in vitro as we observed a dose-
dependent increase of markers LC3B-II and p62 with 
increasing concentrations of autophagy inhibitor CQ. CQ 
prevents the fusion of autophagosomes and lysosomes 
and subsequent degradation. As LC3B-II and p62 is 
incorporated into the autophagosomal membranes and 
subsequently degraded, inhibition at a late stage will 
result in accumulation of these markers and is indicative 
of functional basal autophagy. 
Low p62 staining patterns, regardless of type, 
subcellular localization or combination with LC3B, 
correlated with a worse prognosis. Of note, low p62 
nuclear staining was associated with lymph node 
metastases, a higher grade and with higher stage tumors. 
There was no intratumoral heterogeneity of the staining 
patterns of our autophagy related markers and no 
correlation between them and intratumoral inflammatory 
infiltrates. This was unexpected following the concept 
that autophagy may be strongly linked to inflammation 
and may show specific reaction patterns to different 
environment such as the tumor periphery in contrast 
to the tumor center [14, 15]. Regarding survival, the 
classification of our cohort based on p62 cytoplasmic/p62 
nuclear staining patterns was an independent prognostic 
factor with a significantly worse outcome in patients with 
low cytoplasmic/low nuclear p62 expressing tumors.
At present the literature focusing on the role of 
autophagy in EAC is limited. O’Donovan et al. [16] 
reported that chemoresistant esophageal cancer cell 
lines induce cytoprotective autophagy upon treatment. A 
recent follow up study [17] added that pharmacological 
autophagy inducers rapamycin and lithium had diverging 
effects when combined with chemotherapeutic agents in 
esophageal cancer cell lines. Given the different research 
settings it is difficult to situate our current work in 
relation to the aforementioned studies. Roesley et al. [18] 
table 4: p62 dot-like, p62 cytoplasmic and p62 nuclear staining patterns correlated to clinicopathological features 
respectively. 
Parameter category total p62 dots p62 cytoplasm p62 nuclearlow High p-value low High p-value low High p-value
pT category pT1pT2
pT3
pT4
35
11
67
3
11
6
30
1
24
5
37
2
0.455 01
11
0
35
10
56
3
0.070 126
38
2
23
5
29
1
0.165
Lymph Node 
Metastasis
absent
present
56
60
23
25
33
35 1.000
5
7
51
53 0.764
21
37
35
23 0.015
Distant 
Metastasis
absent
present
111
5
46
2
65
3 1.000
12
0
99
5 1.000
54
4
57
1 0.364
UICC Stage
I
II
III
IV
35
25
51
5
14
11
21
2
21
14
30
3
0.991
0
6
6
0
35
19
45
5
0.021
11
13
30
4
24
12
21
1
0.041
Lymphatic 
Invasion
absent
present
38
78
18
30
20
48 0.423
4
8
34
70 1.000
18
40
20
38 0.843
Venous Invasion absentpresent
87
29
39
9
48
20 0.276
8
4
79
25 0.491
41
17
46
12 0.391
Perineural 
Invasion
absent
present
70
45
29
19
42
26 1.000
7
5
64
40 1.000
31
27
40
18 0.127
Inflammation lowhigh
55
61
26
22
29
39 0.260
4
8
51
53 0.370
26
32
29
29 0.710
Grading
G1
G2
G3
18
50
48
8
22
18
10
28
30
0.886
0
5
7
18
45
41
0.322
9
18
31
9
32
17
0.042
Resection Status R0R1
109
7
43
5
66
2 0.124
11
1
98
6 0.544
56
2
53
5 0.438
Statistically significant p values are shown in bold.
Oncotarget39246www.impactjournals.com/oncotarget
reported that dysplastic BE and EAC have lower levels 
of Beclin-1, an early autophagy initiator, when compared 
to non-dysplastic BE and normal squamous mucosa. This 
contrasts with our study as we observed significantly lower 
levels of LC3B and p62 in normal esophagus and gastric 
mucosa, when compared to the tumor tissue in our cohort. 
We found the autophagy machinery in EAC under basal 
conditions to be intact in vitro. Preliminary experiments 
performed in our group confirmed that pharmacological 
and amino acid starvation autophagy induction in EAC 
cell lines OE19 and OE33 (data not shown). This is in 
contrast to previous reports by Roesley et al., stating that 
dysplastic BE and EAC displays resistance to autophagy 
inducers. These discrepancies can be explained by 
table 5: p62 sum score and clinicopathological features. 
Parameter category total p62 sum low p62 sum High p -value
pT category
pT1
pT2
pT3
pT4
35
11
67
3
2
2
18
0
33
9
49
3
0.059
Lymph Node 
Metastasis
absent
present
56
60
9
13
47
47 0.485
Distant Metastasis absentpresent
111
5
20
2
91
3 0.239
UICC Stage
I
II
III
IV
35
25
51
5
2
9
9
2
33
16
42
3
0.017
Lymphatic 
Invasion
absent
present
38
78
7
15
31
63 1.000
Venous Invasion absentpresent
87
29
15
7
72
22 0.421
Perineural Invasion absentpresent
71
45
11
11
60
34 0.237
Inflammation lowhigh
55
61
14
8
41
53 0.102
Grading
G1
G2
G3
18
50
48
3
7
12
15
43
36
0.415
Resection Status R0R1
109
7
20
2
89
5 0.616
Statistically significant p values are shown in bold.
Table 6: p62 cytoplasmic/p62 nuclear classification was shown to be an independent prognostic parameter in a 
multivariate analysis encompassing pt category, pn category, absence or presence of distant metastasis, lymphatic 
invasion and perineural invasion as well as grading. 
parameter Hr
95% confidence interval
p-value
min max
pT category
pT1 vs pT2 vs pT3 vs pT4 1.505 0.916 2.472 0.106
pN category
pN0 vs pN1 vs pN2 vs pN3 1.396 0.985 1.977 0.061
distant metastases
absent vs present 1.684 0.464 6.110 0.428
lymphatic invasion
absent vs present 1.021 0.374 2.783 0.968
perineural invasion
absent vs present 0.502 0.211 1.195 0.119
Grading
G1 vs G2 vs G3 1.584 0.935 2.685 0.087
p62 cyto/p62 nucl
LL vs mixed/HH 0.561 0.329 0.956 0.033
Statistically significant p-values are shown in bold. HR – Hazard Ratio
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Table 7: p62 cytoplasmic/p62 nuclear classification was shown to be an independent prognostic parameter in a 
multivariate analysis encompassing uIcc and grading. 
Parameter Hr
95% confidence interval
p-value
min max
UICC stage
I vs II vs III vs IV 1.792 1.198 2.682 0.005
Grading
G1 vs G2 vs G3 1.451 0.885 2.380 0.140
p62 cyto/p62 nucl
LL vs mixed/HH 0.549 0.330 0.914 0.021
Statistically significant p-values are shown in bold. HR – Hazard Ratio
Figure 1: eAc exhibits intact basal autophagy in vitro as determined by immunoblotting of markers lc3b and p62 
upon pharmacological autophagy inhibition. A. EAC cell lines OE19 and OE33 were treated with increasing concentrations of the 
autophagy inhibitor chloroquine (CQ) for 48hr followed by immunoblotting of the autophagy markers p62 and LC3B. Total protein was 
visualized as loading control. Representative blot is shown. b. Quantification of triplicate repetitions of experiments shown in A.
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different experimental set ups being used in previous work 
that may not adequately discriminate between an induction 
or a block of autophagy. We observed that lower levels 
of LC3B and p62 correlated with more advanced staged 
tumors. In addition we observed higher levels of both 
markers, when compared to normal matched tissue, in a 
small sample collection of non-dysplastic and dysplastic 
BE tissue (data not shown). Although we did not explicitly 
investigate the role of autophagy in the progression 
of Barrett’s esophagus, these preliminary findings are 
indicative for an important role of autophagy in EAC 
pathogenesis and warrant further investigation. 
El-Mashed et al. identified LC3B cytoplasmic, 
LC3B ring-like structures and LC3B stone-like structures 
in treatment naïve and neoadjuvant treated EAC cohorts 
[19]. LC3B cytoplasmic staining correlated with a better 
overall survival, which is contrast to our study as low 
LC3B dot-like structures, in combination with low p62 
expression, correlated with a shorter overall survival. We 
did not observe globular structures, while only observing 
ring-like structures in a very small subset of cases without 
prognostic significance. The difference in staining patterns 
observed could be explained by the different specificity 
and reactivity of the antibodies used in each study. El-
Figure 2: eAc exhibits intact basal autophagy in vitro as determined by immunofluorescent staining of LC3B upon 
pharmacological autophagy inhibition. A. OE19 and OE33 were treated with increasing concentrations of CQ for 48hr and LC3B 
detected via immunofluorescence. LC3B-II is visualized as green punctae, representing autophagosomes. Nuclei were stained with DAPI 
(blue). Representative images are shown. b. Quantification of triplicate repetitions of experiments shown in A. 
Oncotarget39249www.impactjournals.com/oncotarget
Figure 3: lc3b immunohistochemical staining of barrett’s esophagus (be) and esophageal adenocarcinoma (eAc). A. 
BE tissue with goblet cells and high LC3B dot-like staining. b. EAC tissue with low LC3B dot-like staining and nerves as internal positive 
control. c. and d. EAC tissue with high LC3B dot-like staining. Representative images were taken on a Zeiss Axioskop microscope at 40X 
objective magnification and corrected for brightness.
Figure 4: Immunohistochemical staining patterns of p62 in esophageal adenocarcinoma (eAc). EAC tissue exhibiting A. 
low p62 cytoplasmic staining, b. high p62 cytoplasmic staining c. both high p62 dot-like and diffuse cytoplasmic staining, and d. high 
p62 nuclear positivity. Representative images were taken on a Zeiss Axioskop microscope at 40X objective magnification and corrected for 
brightness. Insert in A. and c. is for better visualization of the hardly visible dots.
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Mashed et al. used anti-LC3B antibody from Abgent 
(rabbit polyclonal, directed at N-terminal 1-30 amino 
acids, AP1802a), while anti-LC3B antibody from Novus 
Biologicals (rabbit polyclonal, directed at N-terminal 
#NB600-1384) was used in our study. It has also been 
published that the anti-LC3B antibody from Novus 
Biologicals shows crossreactivity with LC3A [20]. It has 
been demonstrated that the different isoforms of LC3 is 
differentially expressed in various tissues, however little is 
known about the expression patterns in esophageal normal 
and neoplastic tissue. Furthermore, it has been shown 
that both LC3A and LC3B localized to autophagosomal 
membranes upon induction and are therefore suitable 
markers [21, 22]. While the crossreactivity of the antibody 
in this study can be considered a confounding factor, the 
interpretation of staining patterns remains the same as 
both isoforms are markers for autophagic activity. This 
highlights the importance of standardization of staining 
and scoring protocols of LC3B prior to widespread 
implementation as a routine biomarker. 
Our finding that low p62 expression correlates with 
a more aggressive phenotype, worse prognosis and worse 
overall survival in EAC is in contrast to numerous studies 
done on other tumor entities [23-27], although there 
are also diverging reports about a potential prognostic 
impact of p62 [13]. At present, p62’s role in cancer has 
to be considered context dependent and elucidating the 
underlying mechanism is complicated given the multiple 
functions of p62. 
Figure 5: Kaplan-Meier survival curves for p62 staining patterns in esophageal adenocarcinomas. A. Dot-like, b. 
cytoplasmic or c. nuclear staining classified as either low or high. d. p62 sum score. For each curve the p-value is displayed on the bottom 
right-hand corner.
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It is well described that p62 functions as an adaptor 
protein, which binds ubiquitinated protein aggregates and 
delivers it to autophagosomes via its association with 
LC3B [28]. In addition, p62 has been identified as a major 
player in other pathways. This includes the nuclear factor 
erytheriod-derived-2-like 2 -Kelch-like ECH-associated 
protein 1-antioxidant response element (Nrf2-Keap1-
ARE) pathway, where dysregulated p62 may contribute 
to oncogenesis [9, 23]. p62 also plays a tumor promoting 
role via the nuclear factor kappa B (NF-κB) pathway 
and increased inflammation [29-31]. Given that low 
cytoplasmic p62 correlates with a worse overall survival 
in our EAC cohort it seems unlikely that these pathways 
are contributing factors. p62 has also been described as a 
tumor suppressor as it facilitates autophagic degradation of 
regulators of the oncogenic Wnt signalling pathway [32]. 
It is therefore tempting to speculate that this could be an 
underlying mechanism for the prognostic impact observed 
in our cohort. Furthermore, p62 has been shown to be a 
regulatory player in mitosis and cell cycle regulation [33-
35], and has also been described to mediate an alternative 
nuclear proteolytic degradation pathway [36]. One may 
speculate that the cases with low nuclear p62 expression, 
that were associated with a worse prognosis suffered 
from more nuclear instability/increased nuclear protein 
aggregation, which contributed to disease progression and 
an aggressive phenotype.
To our knowledge this is the first study to investigate 
the prognostic relevance of both autophagy markers 
LC3B and p62 in primary resected EAC. Investigating 
the underlying mechanism as to why low p62 expression 
consistently correlated with a worse patient outcome 
could lead to a better understanding of EAC biology 
and open up novel avenues for therapeutic intervention. 
Basal autophagy, as indicated by low LC3B and p62 
expression, may give tumors access to a continuous 
supply of nutrients and building blocks thereby facilitating 
progression and an aggressive phenotype. Late stage 
impairment of basal or activated autophagy, mirrored 
by mixed or high LC3B and p62 expression, would not 
confer this oncogenic advantage. Given the divergent 
roles of autophagy described in neoplastic diseases this 
is a feasible hypothesis to explain our results. We are 
aware that assessing the dynamic process of autophagy 
using a static IHC ex vivo approach is a limitation. 
However, taken together the results described in this study 
highlight the potential role of autophagy, and other p62 
related pathways, in EAC biology and warrant further 
investigation. 
MAterIAls And MetHods
cell lines, culture and treatment conditions
The human EAC cancer cell lines OE19 and OE33 
from the Public Health England Culture Collections were 
obtained via Sigma-Aldrich, Buchs, Switzerland. The cell 
lines were cultured in RPMI-1640 (Sigma-Aldrich, Buchs, 
Switzerland) supplemented with 10% fetal bovine serum 
Figure 6: Kaplan-Meier survival curves for subcellular location patterns of autophagy markers p62 and lc3b in 
esophageal adenocarcinomas. A. Kaplan-Meier survival curve analysis using classification strategy based on subcellular location 
and expression of p62. The cohort was subdivided into three groups based on their p62 cytoplasmic (including dot-like) and nuclear 
staining patterns: low p62 cytoplasmic/low p62 nuclear (LL), either low p62 cytoplasmic/high p62 nuclear or vice versa (mixed), high 
p62 cytoplasmic/high p62 nuclear (HH). b. Kaplan-Meier survival curve analysis using classification strategy based on LC3B dot-like 
expression and total p62 expression. The cohort was subdivided into three groups: low LC3B/low p62 (LL), either low LC3B/high p62 or 
vice versa (mixed), high LC3B/high p62 (HH). For each curve the p-value is displayed on the bottom right-hand corner.
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(Sigma-Aldrich, F7524) and 1% penicillin streptomycin. 
Chloroquine (Sigma-Aldrich, C6628) was dissolved in 
distilled water and stored at -20°C. Chloroquine (CQ) 
inhibits late stage autophagy by increasing lysosomal pH 
thereby preventing the autophagosome-lysosome fusion 
and subsequent degradation of autophagic flux markers 
LC3B-II and p62. Lipidated form of LC3B-II migrates 
faster than the unlipidated LC3B-I on an SDS-PAGE 
gel and therefore the two isoforms can be separated and 
visualized using immunoblotting. Cells were seeded in a 
6 well dish and allowed to adhere overnight and CQ was 
added to the experimental wells the following day at final 
concentrations of 25µM and 50µM and incubated for 
48hr prior to harvesting or fixing of cells for subsequent 
immunoblotting or immunofluorescence respectively. 
Immunoblotting
OE19 and OE33 cells were washed in phosphate 
buffered saline (PBS) before lysis in urea buffer (8 M urea, 
0.5% tritonX) containing protease inhibitor (complete 
midi, Roche Diagnostics, Rotkreuz, Switzerland). 
Samples were then sonicated and centrifuged at 13,000 
rcf for 30min. Supernatant was subsequently transferred 
to a fresh tube. Protein concentration was determined 
using the Bradford protein assay (BioRad, Cressier, 
Switzerland). Thirty μg of total protein were denatured 
in selfmade 5X sample buffer with β-mercaptoethanol 
(Sigma Aldrich, M-7522) at 95°C for 5 min. Samples were 
loaded on a 4-20% stain-free pre-cast gel (BioRad) and 
transferred onto a polyvinylidene difluoride membrane 
using the Trans-Blot® Turbo™ Transfer system (BioRad). 
Total protein was visualized as loading control using the 
ChemiDoc™ MP system (BioRad). Primary antibodies 
were purchased as follows: the anti-LC3B antibody from 
Novus Biologicals (rabbit polyclonal, #NB600-1384, 
LuBioScience, Luzern, Switzerland) and the anti-p62/
SQSTM1 antibody from Sigma (mouse monoclonal, clone 
2C11, #WH0008878M1, Leiden, The Netherlands). For 
p62 membranes were blocked in 5% milk/tris-buffered 
saline (TBS) for 1hr at room temperature (RT), while 
membranes for LC3B were blocked in 5% bovine serum 
albumin (BSA)/TBS for 1hr at RT. Working solutions of 
the primary LC3B and p62 antibodies were prepared with 
final dilution 1:1000 in 5% milk/TBS with 0.1% Tween 
(Sigma Aldrich, P9416). Membranes were incubated 
overnight at 4°C with shaking. DyLight®650 conjugated 
goat anti-rabbit or DyLight®550 conjugated goat anti-
mouse (LabForce, Muttenz, Switzerland) was used as 
secondary antibodies and diluted 1:1000 in 5% milk/
TBS-T. Membranes were incubated for 1hr at RT with 
shaking. Proteins of interest were acquired and visualized 
using the ChemiDoc™ MP system (BioRad). Bands were 
quantified using ImageJ software (1.64r; NIH, Bethesda, 
MD, USA).
Immunofluorescence
OE19 and OE33 was seeded directly onto cover-
slides (18mmX18mm) in a 6well plate and allowed to 
adhere overnight. Cells remained untreated or treated 
with 25µM and 50µM Chloroquine (CQ) for 48hr prior 
to fixation. Cells were washed in PBS, pre-fixed in 4% 
paraformaldehyde for 15 seconds, fixed and permeabilized 
in ice-cold 100% methanol for 10min at -20°C. Slides were 
air dried and washed with PBS prior to incubation with 
the primary anti-LC3B antibody (Cell Signaling, Lausen, 
Switzerland, rabbit monoclonal,clone D11, #3686,) at a 
working dilution of 1:100 in PBS/1%BSA/0.1%Tween 
for 1hr at RT. Subsequently slides were washed twice 
with PBS 0.1% Tween and once with PBS and incubated 
for 1hr at RT with the fluorescein isothiocyanate (FITC) 
conjugated antirabbit secondary antibody (#111-096-045 
Jackson Immunoresearch, Suffolk, UK) in a working 
dilution of 1:130 in PBS/1%BSA/0.1% Tween. Slides 
were once again washed twice with PBS 0.1% Tween 
and once with PBS. Slides were allowed to air dry. 
Mounting media (Thermofisher Scientific, Reinach, 
Switzerland, S36938) containing DAPI (4’,6-diamidino-
2-phenylindole) was added to slides in order to visualize 
nuclei. Images were taken on a confocal microscope 
Olympus FluoView1000 at 63x objective magnification. 
Images were adjusted for brightness and the number of 
LC3B positive dots was quantified using ImageJ software 
(1.64r; NIH, Bethesda, MD, USA), using a modified 
plugin as previously described [37].
Patients and tissue samples
Patient tissue of esophageal adenocarcinoma 
resection specimens was collected from the archive of 
the Institute of Pathology, University of Bern, Bern, 
Switzerland. The patients were consecutively treated 
between 1991 and 2011 at the Department of Visceral 
Surgery of the Inselspital, Bern, Switzerland. We selected 
only cases that were primarily resected without prior 
neoadjuvant chemo- or radiochemotherapy or adjuvant 
treatment. The use of human archival pathological 
tissue for TMA based studies was approved by the local 
ethics committee (Kantonale Ethikkommission Bern, 
Switzerland, 200/14: Identification of novel prognostic 
and predictive biomarkers using tissue microarrays 
(TMAs) constructed at the INSTITUTE of Pathology, 
University of Bern).
tissue microarray
Buffered formalin fixed paraffin embedded (FFPE) 
tissue from primary resected EAC (n = 116; three 
punches taken from tumor center and tumor periphery 
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respectively), Barrett’s mucosa (n = 21), adjacent non-
neoplastic esophageal mucosa (n = 60), adjacent non-
neoplastic gastric mucosa (n = 68), EAC lymph node 
metastasis (n = 58) and EAC distant metastasis (n = 18) 
was used to construct a next generation tissue microarray 
(ngTMA), with digital annotation of scanned slides 
and automatic transferal of the punches, as previously 
described [38]. Three punches from each location were 
transferred to the TMA acceptor block from each tissue 
(0.6 mm punches). 
Immunohistochemical staining, scoring and 
subclassification
The ngTMA was sectioned at 4 μm. After de-
paraffination, rehydration, and antigen retrieval, 
immunohistochemical staining was performed using an 
automated immunostainer (Bond RX, Leica Biosystems, 
Heerbrugg, Switzerland) as previously described [10]. 
Briefly the anti-LC3B antibody (Novus Biologicals 
#NB600-1384) was diluted 1:4000 in tris buffer and 
incubated at 95°C for 30 min. The anti-p62/SQSTM1 
antibody (MBL rabbit polyclonal, #PM045, LabForce, 
Nunningen, Switzerland) was diluted 1:9000 in tris 
buffer and incubated at 95°C for 30 min. Visualization 
was performed using the Bond Polymer Refine 
Detection kit (Leica Biosystems, product number) per 
manufacturer’s instructions. IHC stainings were scored 
according to a previously established protocol [10]. The 
immunohistochemical stainings were independently 
scored by two observers (OA and RL) on a Zeiss Axioskop 
microscope at 40x objective magnification. Discrepant 
results were re-evaluated at a double-header microscope. 
For the purpose of further analysis IHC scores 
were categorized as either “low” or “high” for each 
staining pattern according to the prognostic impact of 
the single scores (for survival curves of individual scores 
see Supplementary Figures 2 and 3). For LC3B dot-like 
staining scores 0 and 1 were classified as low, while scores 
2 and 3 were classified as high. The low category of p62 
dot-like staining was assigned to score 0, while scores 1, 
2 and 3 were assigned to the high category. The scores 
for p62 cytoplasmic staining were similarly subdivided, 
while score 0 for p62 nuclear staining was classified as 
low and scores 1 and 2 as high. Finally a p62 sum score 
was calculated by adding the individual scores of the dot-
like, cytoplasmic and nuclear staining patterns together. 
The p62 sum score ranged from 0 to 6. Subsequently the 
p62 sum score was also subdivided in low (score 0 and 1) 
and high (from score 2 to 6) groups.
According to work published by Iwade et al. [12] 
we stratified our dataset into four subtypes with respect 
to p62 staining patterns and subcellular location: low p62 
cytoplasmic/low p62 nuclear (LL), high p62 cytoplasmic/
low p62 nuclear (HL), low p62 cytoplasmic/high p62 
nuclear (LH) and high p62 cytoplasmic/high p62 nuclear 
(HH). The cytoplasmic score was calculated by adding 
the dot-like and cytoplasmic staining scores together 
with scores 0 and 1 being classified as low and scores 
2 through 5 being classified as high (see Supplementary 
Figure 3). The HL and LH categories were combination 
into a “mixed” group and used for subsequent analysis. 
According to Liu and colleagues [13] we stratified our data 
set according to LC3B and p62 staining patterns, resulting 
in three groups: low LC3B/low p62 (LL), mixed (low 
LC3B/high p62 or vice versa) and high LC3B/high p62. 
In the context of this analysis the p62 sum score low/high 
categories were used as previously mentioned. 
Host inflammatory response to the tumors were 
scored according to Brown et al., who recognized three 
different grades; i.e. sparse, moderate and pronounced 
based on histomorphology by Hematoxylin & Eosin 
staining [39]. For the purpose of this study this grading 
was simplified into low (sparse) and high (moderate and 
high) with an equal distribution of the two categories 
and estimated across all six TMA punches. Examples 
of low and high inflammatory response are given in 
Supplementary Figure 5.
statistical analysis
The SPSS 23 software (SPSS Inc, Chicago, IL, 
USA) was used for descriptive and comparative statistical 
analysis. Associations between staining patterns and 
clinicopathological parameters were evaluated using 
simple cross tabs (χ²-test or Fisher’s exact test). Binded 
samples were evaluated using the Wilcoxon test. Survival 
analysis was performed using log rank test and Cox 
regression analysis (inclusion). The significance level was 
set at 0.05.
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